Heron Therapeutics Inc. (NASDAQ:HRTX) had its target price decreased by equities researchers at Jefferies Group from $46.00 to $40.00 in a research note issued to investors on Monday, StockTargetPrices.com reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Jefferies Group’s price objective points to a potential upside of 132.15% from the company’s previous close.
Other analysts also recently issued research reports about the stock. Cantor Fitzgerald restated a “buy” rating and set a $41.00 price target on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Cowen and Company reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Leerink Swann reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Monday, June 27th. Brean Capital reaffirmed a “buy” rating and set a $55.00 price objective on shares of Heron Therapeutics in a research report on Saturday, August 13th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Friday, September 9th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $44.14.
Shares of Heron Therapeutics (NASDAQ:HRTX) traded down 8.13% during trading on Monday, hitting $15.83. The stock had a trading volume of 648,642 shares. Heron Therapeutics has a one year low of $15.13 and a one year high of $31.32. The stock’s 50 day moving average price is $19.21 and its 200-day moving average price is $18.91.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. On average, equities analysts forecast that Heron Therapeutics will post ($4.44) earnings per share for the current year.
In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total value of $2,330,000.00. Following the completion of the transaction, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 20.31% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. boosted its stake in Heron Therapeutics by 28.2% in the first quarter. Franklin Resources Inc. now owns 7,523,278 shares of the biotechnology company’s stock valued at $142,869,000 after buying an additional 1,653,008 shares during the period. JPMorgan Chase & Co. boosted its stake in Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock valued at $6,622,000 after buying an additional 19,737 shares during the period. VHCP Management II LLC purchased a new stake in Heron Therapeutics during the first quarter valued at about $7,708,000. Jacobs Levy Equity Management Inc. purchased a new stake in Heron Therapeutics during the first quarter valued at about $734,000. Finally, Panagora Asset Management Inc. boosted its stake in Heron Therapeutics by 90.3% in the first quarter. Panagora Asset Management Inc. now owns 245,392 shares of the biotechnology company’s stock valued at $4,660,000 after buying an additional 116,461 shares during the period.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.